Palatin Technologies Inc (PTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Palatin Technologies Inc (Palatin) is a biopharmaceutical company. It is focused on developing therapeutics targeting the melanocortin receptor (MCr) system, which is vital for functions like inflammation and metabolism. The company focuses on obesity and male sexual dysfunction, recently launching a Phase 2 trial for bremelanotide combined with tirzepatide to enhance weight loss efficacy. Palatin is working on a co-formulated bremelanotide with a PDE5 inhibitor for erectile dysfunction. Its lead candidate, PL9643, targets dry eye disease, with a successful Phase 3 trial underway. The company is also conducting a Phase 2 study for PL8177, targeting inflammatory bowel diseases, while also progressing with research for diabetic nephropathy and diabetic retinopathy. Palatin is headquartered in Cranbury, New Jersey, the US.Palatin Technologies Inc Key Recent Developments
- Oct 23, 2024: Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
- Sep 09, 2024: Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
- May 16, 2024: Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
- Jan 08, 2024: Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eton Pharmaceuticals Inc
- MEI Pharma Inc
- Savara Inc
- Talphera Inc
- Verastem Inc
- Ardelyx Inc